Development of a diagnostic marker and method for pancreatic cancer using secretome and proteome analysis.

点击翻译按钮获取中文摘要

In this study, we employed a quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) followed by mass spectrometry to quantify changes in protein levels between gemcitabine resistant and sensitive pancreatic cancer cells. The 120 proteins were shown more than 2-fold change between the resistant and sensitive cell lines, of which twenty proteins were confirmed by WB. Moreover, 30 proteins were changed more than two times in the comparative analysis of membrane proteins. The siRNA-mediated inhibition of protein expression which was increased in resistant cells increased the cytotoxic effect of gemcitabine. We identified the candidate proteins of diagnosis marker in secretome analysis, the validation of candidate proteins in the serum is now underway.